The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.

The government agency says X no longer suits its communication needs.

The use of the ESMP will become mandatory for MAHs and NCAs as of Sunday, February 2. The platform is a key requirement of the European Medicines Agency’s extended mandate, enhancing shortages monitoring and preparedness across the European Union (EU)/European Economic Area (EEA).

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...

The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will instead post its updates on fast-growing rival Bluesky.

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back from X,

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here.

Submission supported by positive results from global, Phase 3 4WHIM clinical trial;U.S. regulatory approval in WHIM syndrome granted in

the agency added, saying it did not pose a risk to human or animal health. The EMA's recommendation will now be sent to the European Commission to adopt a decision for EU-wide marketing authorisation.

Thiogenesis Therapeutics, and Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds,

Pharma: Launch of Shortages Monitoring Platform, several Changes re Clinical Trial Management in EU Countries; Devices: Resolution on the need